At-risk group responds well to Moderna vaccine

27 August 2020

Phase I data presented at a meeting of the CDC’s Advisory Committee on Immunization Practices show a positive response to Moderna’s (Nasdaq: MRNA) COVID-19 vaccine.

The Centers for Disease Control (CDC) panel heard results, not yet published by the company but submitted for peer review, which show older people responded well, a key factor given the high impact of the disease on this demographic.

Following dosing with mRNA-1273, neutralizing antibodies detected in a small number of adults aged 56 to 70 were at a similar level to those found in a group aged 18 to 55.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK